Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
grade F 3.18 -5.64% -0.19
ABUS closed down 5.64 percent on Thursday, April 18, 2019, on 3.79 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ABUS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Volume Surge Other 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -5.64%
Stochastic Reached Oversold Weakness -5.64%

Older signals for ABUS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Biopharmaceutical Medical Specialties Infectious Diseases Hepatitis B Hepatocellular Carcinoma Hypercholesterolemia PLK1 Sexually Transmitted Diseases And Infections Zoonoses Arbutus Biopharma Liver Cancer Primary Hyperoxaluria Transthyretin Amyloidosis Tropical Diseases
Is ABUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 12.6
52 Week Low 3.18
Average Volume 191,449
200-Day Moving Average 6.0836
50-Day Moving Average 3.8842
20-Day Moving Average 3.8015
10-Day Moving Average 3.807
Average True Range 0.2674
ADX 17.07
+DI 15.2143
-DI 30.522
Chandelier Exit (Long, 3 ATRs ) 3.7578
Chandelier Exit (Short, 3 ATRs ) 3.9822
Upper Bollinger Band 4.4771
Lower Bollinger Band 3.1259
Percent B (%b) 0.04
BandWidth 35.543864
MACD Line -0.1058
MACD Signal Line -0.0212
MACD Histogram -0.0845
Fundamentals Value
Market Cap 174.98 Million
Num Shares 55 Million
EPS -5.07
Price-to-Earnings (P/E) Ratio -0.63
Price-to-Sales 164.81
Price-to-Book 1.74
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.54
Resistance 3 (R3) 3.58 3.50 3.48
Resistance 2 (R2) 3.50 3.41 3.48 3.46
Resistance 1 (R1) 3.34 3.35 3.30 3.30 3.44
Pivot Point 3.26 3.26 3.24 3.24 3.26
Support 1 (S1) 3.10 3.17 3.06 3.06 2.92
Support 2 (S2) 3.02 3.11 3.00 2.90
Support 3 (S3) 2.86 3.02 2.88
Support 4 (S4) 2.82